There are a number offactors (planning, process optimization, organizational structure, people development and the need to see the total picture) that must be in place for automation to be as effective as possible. This paper discusses these factors and their relationship with automation. It evaluates less obvious areas associated with automation, as well as the more established ones, and discusses the premise that it is the integration of all these aspects that truly offers the biggest opportunities.
Introduction
Over the last few years, the pharmaceutical industry has steadily become more competitive. Clear evidence of this is seen in the number of mergers and takeovers that have occurred in the last five to seven years. There is no reason to assume that this state of affairs will get anything but worse as we approach the next millennium. For companies to be successful, they need a source of breakthrough molecular entities, and a development process that permits the drug to move effectively from discovery through IND to NDA or equivalent.
Thus, many companies are re-engineering their development processes to achieve the latter and give them a competitive edge. These processes must be able to significantly reduce the development time, for example by 25-30%, while, at the very least, maintaining quality. They must be achieved without a burnout of staff, an event which unfortunately is becoming steadily more common in the industry.
To further exacerbate the problems, the complexity of the development process significantly increases each year, as do the registration requirements around the world. In 
